Madrigal Pharmaceuticals (MIL:1MDGL) LT-Debt-to-Total-Asset: 0.28 (As of Mar. 2026)


MIL:1MDGL Madrigal Pharmaceuticals Inc MIL:1MDGL
8 GF Score
Price €460.60
! 4 Warning Signs
View Full Analysis

What is Madrigal Pharmaceuticals LT-Debt-to-Total-Asset?

Madrigal Pharmaceuticals MIL:1MDGL 8 LT-Debt-to-Total-Asset is 0.28 as of Mar. 2026. GuruFocus rates MIL:1MDGL with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Madrigal Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.28.

Madrigal Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2025 (0.12) to Mar. 2026 (0.28). It may suggest that Madrigal Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Madrigal Pharmaceuticals  (MIL:1MDGL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Madrigal Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Madrigal Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Madrigal Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Madrigal Pharmaceuticals LT-Debt-to-Total-Asset Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.14 0.18 0.11 0.28

Madrigal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.25 0.28 0.28
MIL:1MDGL
8GF Score
Madrigal Pharmaceuticals Inc MIL:1MDGL
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Madrigal Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Madrigal Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=296.007/1075.689
=0.28

Madrigal Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=298.956/1061.638
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.28 mean?
Madrigal Pharmaceuticals (MIL:1MDGL) has a LT-Debt-to-Total-Asset of 0.28 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Madrigal Pharmaceuticals and its competitors.
Is Madrigal Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Madrigal Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.28. Overall, Madrigal Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' LT-Debt-to-Total-Asset compare to BMRN and AXSM?
Madrigal Pharmaceuticals' LT-Debt-to-Total-Asset of 0.28 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MIL:1MDGL) has a current LT-Debt-to-Total-Asset of 0.28. The current LT-Debt-to-Total-Asset is 0.28. Madrigal Pharmaceuticals' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MIL:1MDGL), the current LT-Debt-to-Total-Asset is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Madrigal Pharmaceuticals Business Description

Other Exchanges MDGL:USA0JXI:UKYDO1:Germany
Address 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score

Get the complete analysis for MIL:1MDGL

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€460.60
Price